Antimicrobial susceptibility and toxin production of Clostridium difficile isolated from diarrheal patients during 2012-2015
Article Sidebar
Main Article Content
Abstract
Background: Clostridium difficile infection affects people who have been treated with antibiotics and long-term care facilities. C. difficile release two protein toxins, toxin A and toxin B that are the major virulence factors. C. difficile plays important role in hospital-associated diarrhea around the world with wide range of clinical symptoms from asymptomatic carrier, mild to severe diarrhea, colitis, pseudomembranous colitis.
Objectives: To investigate the prevalence of toxigenic C.difficile by multiplex PCR and to determine antimicrobial susceptibility of C. difficile isolated from diarrheal patients using agar dilution method.
Materials and methods: A total of 49 isolates of C. difficile from stool specimens of diarrheal patients with suspected antibiotic-associated diarrhea during 2012-2015 were included. Detection of toxin genes by multiplex PCR and minimum inhibitory concentration (MIC) by agar dilution were performed.
Results: C. difficile isolates were classified into three groups according to toxin genes found as following 1) negative detection of types A and B toxin genes (A-B-) (29 isolates, 3.36%), 2) negative detection of type A toxin gene but positive detection of type B toxin gene (A-B+) (14 isolates, 1.62%), 3) positive detection of type A and B toxin genes (A+B+) (6 isolates, 0.69%). Binary toxin genes were not found in any isolate. Results of MIC for 9 drugs were as following; all isolates were sensitive to vancomycin (MIC 0.25-1 μg/mL) and Metronidazole (MIC 0.25-2 μg/mL). All isolates were resistant to clindamycin (MIC=8 to >256 μg/ml, MIC50=32 μg/mL). Approximately 65.7% of isolates were sensitive to moxifloxacin (MIC 1-4 μg/mL). Most isolates were sensitive to tetracycline (MIC<0.125-4 μg/mL) and sensitive to chloramphenical (MIC 0.25-8 μg/mL). Antimicrobial susceptibility test of levofloxacin, gemifloxacin and erythromycin were performed without criteria of breakpoint, MIC of these drugs were obtained as followings: 2 to >128 μg/mL (MIC50=4 μg/mL), 0.5-32 μg/mL (MIC50=1 μg/mL) and 0.125-128 μg/mL (MIC50=2 μg/mL), respectively.
Conclusion: Antimicrobial susceptibility and toxin production of C. difficile are useful for monitoring the severity of disease and rate of resistant to antibiotics. The study found that the majority of metronidazole and vancomycin were effective for treatment of C. difficile diarrheal infection in Thailand.
Journal of Associated Medical Sciences 2017; 50(2): 187-196. Doi: 10.14456/jams.2017.14
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
2. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17(1): 109-13.
3. Bartlett JG. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994; 18 Suppl 4: S265-72.
4. McADam AJ, Sharpe AH. Infectious diseases. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia: Elsevier; 2010. p. 367-444.
5. Wells CL, Wilkins TD. Clostridia: Spore forming Anaerobic Bacilli. In: Baron S, editor. Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 18.
6. Lyerly DM, Lockwood DE, Richardson SH, Wilkins TD. Biological activities of toxins A and B of Clostridium difficile. Infect Immun 1982; 35: 1147–50.
7. Chia JH, Lai HC, Su LH, Kuo AJ, Wu TL. Molecular Epidemiology of Clostridium difficile at a Medical Center in Taiwan: Persistence of Genetically Clustering of A-B+ Isolates and Increase of A+B+ Isolates. PLoS ONE 2013; 8(10): e75471.
8. Pennisi E. [Online]. 2012. Available from: URL:http://www.sciencemag.org/news/2012/10/using gut-bacteria-fight-diarrhea
9. Komatsu M, Kato H, Aihara M, Shimakawa K, Iwasaki M, Nagasaka Y, et al. High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection. Eur J Clin Microbiol Infect Dis 2003; 22: 525–9.
10. Iwashima Y, Nakamura A, Kato H, Wakimoto Y, Wakiyama N, Kaji C, et al. A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother 2010; 16: 329–33.
11. Chung Y, Chung GT, Seong WK, Oh HB: Molecular Analysis of Clostridium difficile Isolates by Arbitrarily Primed-Polymerase Chain Reaction and Polymerase Chain Reaction-Ribotyping. Korean J Infect Dis 2002; 34: 167-75.
12. Kim H, Riley TV, Kim M, Kim CK, Yong D, Lee K, et al. Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: impact on laboratory diagnosis. J Clin Microbiol 2008; 46: 1116-7.
13. Wongwanich S, Rugdeekha S, Pongpech P, Dhiraputra C. Detection of Clostridium difficile toxin A and B genes from stool samples of Thai diarrheal patients by polymerase chain reaction technique. J Med Assoc Thai 2003; 86(10): 970-5.
14. Thipmontree W, Kiratisin P, Manatsathi S, Tham-likitkul V. Epidemiology of suspected Clostridium difficile-associated hospital acquired diarrhea in hospitalized patients at Siriraj Hospital. J Med Assoc Thai 2011; 94 (1): 207-16.
15. Pupaibool J, Khantipong M, Suankrata C. A study of Clostridium difficile-associated disease at King Chulalongkorn Memorial Hospital, Thailand. J Med Assoc Thai 2008; 91(1): 37-43.
16. Hu MY1, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridum difficile infection. Gastroenterology 2009; 136: 1206-14.
17. Kyne L1, Merry C, O’Connell B, Kelly A, Keane C, O’Neill D. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999; 28: 107.
18. Laksamana N, Jearjesdakul J. Antibiotic associated diarrhea. The gastroenterological Association of Thailand. 2009; 17(83): 25-39. (in Thai)
19. Cecil JA. Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures. Curr Infect Dis Rep 2012; 14: 612–9.
20. Supcharassaeng S, Suankratay C. Antibiotic prescription for adults with acute diarrhea at King Chulalongkorn Memorial Hospital, Thailand. J Med Assoc Thai 2011; 94: 545–50.
21. Wongwanich S, Ramsiri S, Vanasin B, Khowsaphit P, Tantipatayangkul P, Phan-urai R. Clostridium difficile associated disease in Thailand. SE Asian J Trop Med 1990; 21(3): 367–72.
22. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 8th ed. CLSI document M11-A8. Wayne, PA: CLSI, 2012.
23. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning a laboratory manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989.
24. Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004; 42: 5710-4.
25. Samie A, Obi CL, Franasiak J, Archbald-Pannone L, Bessong PO, Alcantara-Warren C, et al. PCR detection of Clostridium difficile triose phosphate isomerase (tpi), toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA, cdtB), and tcdC genes in Vhembe District, South Africa. Am J Trop Med Hyg 2008; 78: 577-85.
26. Delmee M. Laboratory diagnosis of Clostridium difficile disease. Clin Microbiol Infect 2001; 7: 411–6.
27. Putsathit P, Kiratisin P, Ngamwongsatit P, Riley TV. Clostridium difficile infection in Thailand. Int J Antimicrob Agents 2015; 45: 1-7.
28. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009; 5: e1000626
29. Lozniewski A, Rabaud C, Dotto E, Weber M, Mory F. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001; 39: 1996-8.
30. Lim PL, Ling ML, Lee HY, Koh TH, Tan AL, Kuijper EJ, et al. Isolation of the first three cases of Clostridium difficile polymerase chain reaction ribotype027 in Singapore. Singapore Med J 2011; 52(5): 361-4.
31. Iwashima Y, Nakamura A, Kato H, Wakimoto Y, Wakiyama N, Kaji C, et al. A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother 2010; 16: 329-33.
32. Lyras D, O’Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T,Poon R, Adams V, Vedantam G, Johnson S, et al: Toxin B is essential forvirulence of Clostridium difficile. Nature 2009, 458: 1176–9.
33. Alfa MJ, Kabani A, Lyerly D, Moncrief S, Neville LM, Al-Barrak A, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2706-14.
34. Drudy D, Fanning S, Kyne L: Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis 2007; 11: 5-10.
35. Collins DA, Hawkey PM, Riley TV Epidemiology of Clostridium difficile infection in Asia. Antimicrob Resist Infect Control. 2013; 2(1): 21.
36. Kim H, Jeong SH, Roh KH, Hong SG, Kim JW, Shin MG, et al. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 2010; 30(5): 491-7.
37. Huang H, Fang H, Weintraub A, Nord CE. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect 2009; 15(12): 1170-3.
38. Spigaglia P, Barbanti F, Mastrantonio P. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 2011; 66(10): 2227-34.
39. Wongwanich S, Pongpech P, Dhiraputra C, Huttayananont S, Sawanpanyalert P. Characteristics of Clostridium difficile strains isolated from asymptomatic individuals and from diarrheal patients. Clin Microbiol Infect 2001; 7: 438-41.
40. Taori SK, Hall V, Poxton IR. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 2010; 59 (3): 338-44.
41. Lakhi N, Ahmad F, Woothipoom W. Clostridium difficile associated diarrhea and the relationship to antibiotic prescription practices and proton pump inhibitor use in elderly wards. Iran Red Crescent Me 2010; 12(1): 12-6.